Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Editorial: The Role of Genetic and Lifestyle Factors in Metabolic Diseases

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  2. Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. In-utero Exposure to Maternal Stressful Life Events and Risk of Cryptorchidism: The Raine Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The origin and understanding of the incretin concept

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Renoprotection with Semaglutide and Liraglutide: Direct or Indirect Effects?

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  2. Endogenous glucose-dependent insulinotropic polypeptide exerts diverging and tissue specific in obese patients with type 2 diabetes

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  3. The glucagon-like peptide-1 receptor agonist, liraglutide, does not suppress postprandial cholecystokinin in patients with type 1 diabetes

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  4. The role of glucagon-like peptide 1 for the postprandial effects of metformin in type 2 diabetes

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Vis graf over relationer

Along the obesity pandemic, the prevalence of non-alcoholic fatty liver disease (NAFLD), often regarded as the hepatic manifestation of the metabolic syndrome, increases worldwide representing now the prevalent liver disease in western countries. No pharmacotherapy is approved for the treatment of NAFLD and, currently, the cornerstone treatment is lifestyle modifications focusing on bodyweight loss, notoriously difficult to obtain and even more difficult to maintain. Thus, novel therapeutic approaches are highly demanded. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are approved for the treatment of type 2 diabetes and obesity. They exert their body weight-lowering effect by reducing satiety and food intake. GLP-1RAs have also been shown to reduce liver inflammation and fibrosis. Furthermore, glucagon receptor agonism is being investigated for the treatment of NAFLD due to its appetite and food intake-reducing effects, as well as its ability to increase lipid oxidation and thermogenesis. Recent studies suggest that glucagon receptor signaling is disrupted in NAFLD, indicating that supra-physiological glucagon receptor agonism might represent a new NAFLD treatment target. The present review provides (1) an overview in the pathophysiology of NAFLD, including the potential involvement of GLP-1 and glucagon, (2) an introduction to the currently available GLP-1RAs and (3) outlines the potential of emerging GLP-1RAs and GLP-1/glucagon receptor co-agonists in the treatment of NAFLD.

OriginalsprogEngelsk
TidsskriftFrontiers in Endocrinology
Vol/bind9
Sider (fra-til)649
ISSN1664-2392
DOI
StatusUdgivet - 6 nov. 2018

ID: 55693912